A Phase 1 interventional study of LY4247147 and LY4247147 in Obesity and Overweight, sponsored by Eli Lilly and Company. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 93rd largest by planned enrollment of the 117 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 1, reaches primary completion later than 45 of the 53 other live ones, and was the 118th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Eli Lilly and Company · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 267 across the 117 interventional studies. Of the 62 that completed or were terminated, 29 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
29 of the studies in Obesity by Eli Lilly and Company that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
Add all 29 to your calendar (.ics) → With an account.
Among the 118 studies in Obesity by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.
The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY4247147 administered subcutaneously (SC)
Drug: LY4247147
Placebo administered SC
Drug: Placebo
LY4247147 administered SC
Drug: LY4247147
Placebo administered SC
Drug: Placebo
LY4247147 administered intravenously (IV)
Drug: LY4247147
administered SC
administered IV
administered SC
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through End of the Follow-up (Estimated as Week 25)
Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through End of the Follow-up (Estimated as Week 33)
Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4247147
Time frame: Predose on Day 1 through Week 25
Part B: PK: Cmax of LY4247147
Time frame: Predose on Day 1 through Week 33
Part A: PK: Time of Maximum Observed Drug Concentration (Tmax) of LY4247147
Time frame: Predose on Day 1 through Week 25
Part B: PK: Tmax of LY4247147
Time frame: Predose on Day 1 through Week 33
Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4247147
Time frame: Predose on Day 1 through Week 25
Part B: PK: AUC of LY4247147
Time frame: Predose on Day 1 through Week 33
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Oct 2028, 23 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 23 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.